Francisca Silva - Psychedelic medicines in the EU

Psychedelic therapies continue to gain traction in European healthcare, requiring meticulous regulatory navigation and evidence-based research development. Efforts focus on the path to clinical integration, emphasizing the importance of aligning new trial methodologies with existing regulatory frameworks. The European Medicines Agency plays a pivotal role, recently updating clinical guidelines for depression to incorporate more specific considerations for psychedelic treatments. Research initiatives, like the first EU-funded, multi-center PsyPal study, demonstrate a growing commitment to exploring the therapeutic potential of psilocybin across various medical conditions, including COPD, ALS, MS, and atypical Parkinsonism. These developments underscore the ongoing necessity for multi-stakeholder collaboration to bridge gaps between research, policy, and eventual clinical application, ensuring therapies remain safe, ethical, and accessible.